A pharmaceutical company linked to GOP presidential candidate Vivek Ramaswamy is facing legal trouble’s over COVID-19 mRNA vaccine technology.
A second biotech firm connected to Pfizer’s vaccine is suing Genevant Sciences, a Roivant Sciences portfolio business, for proprietary COVID vaccine technology. Genevant Sciences is also being sued by Moderna.
Roivant Sciences was founded by Ramaswamy, who served as its CEO from 2014 until 2021. He served as its board chairman up until February of this year, at which point he resigned. He is not a party to the legal dispute.
In February 2022, Genevant Sciences and partner Arbutus Biopharma Corporation filed a lawsuit against Moderna for claimed patent infringement. In April of this year, Genevant Sciences filed a lawsuit against Pfizer and BioNTech.
Moderna is accused of violating an Arbutus patent for a lipid nanoparticle (LNP) delivery platform for the vaccine, which was required “to safeguard the mRNA and deliver it into cells,” according to the lawsuit. The plaintiffs contend that Moderna’s failure to acquire a license to use the LNP patents for COVID was the cause of the infringement.
LNP technology from Arbutus is licensed by Genevant.
According to a news statement, Arbutus and Genevant “do not seek an injunction or otherwise to impede the sale, manufacture or distribution” of the vaccine. As opposed to this, the businesses “seek only fair compensation for the use of patented technology they developed with great effort and expense, without which Moderna’s COVID-19 vaccine would not have been successful.”
A federal court judge refused to partially dismiss the case against Moderna in March of this year, allowing it to proceed.
On Wednesday, Moderna declined to answer right away when asked.
Arbutus and Genevant claimed that Pfizer and BioNTech “never paid Plaintiffs to use” the LNP technologies for the COVID vaccine in their April lawsuit for patent infringement.
Pfizer and BioNTech didn’t immediately respond to requests for comment on Wednesday.
Genevant declined to comment on its lawsuits against Pfizer, BioNTech, and Moderna.
Meanwhile, Arbutus and Genevant are facing a lawsuit from Acuitas Therapeutics
, which was filed in March 2022.
According to the lawsuit, Acuitas, which “partnered with non-parties BioNTech and Pfizer to supply and license the LNP used in COMIRNATY,” the COVID vaccine from Pfizer and BioNTech, alleges that Arbutus and Genevant were not part of creating the technology used for the vaccine.
The defendants “had nothing to do with [the] success” of the Pfizer and BioNTech COVID vaccine, according to the lawsuit.
“Neither has a COVID-19 vaccine, neither has created any component of such a vaccine, and neither has commercialized an LNP that can effectively wrap and protect any mRNA molecule,” the filing also states.
The lawsuit also alleges “Genevant seeks hundreds of millions, if not billions, of dollars in unjustified royalties on sales of COMIRNATY. That demand hinders the ability of Acuitas, as well as its partners such as BioNTech and Pfizer, to freely research, develop, and commercialize therapeutics utilizing Acuitas’s LNP technology, including COVID-19 vaccines.”
According to the lawsuit, “non-party Roivant Sciences Ltd. owns approximately 84% of Genevant Sciences Ltd., and Arbutus owns the remaining approximately 16% of Genevant Sciences Ltd.”
Genevant and Arbutus didn’t immediately respond to requests for comment regarding the Acuitas lawsuit.
Ramaswamy has not respond to a request for comment.
Acuitas said on Thursday that it doesn’t “comment on matters before the court.”
The COVID vaccination boosters are being received less frequently by Americans, and vaccine mandates have been contested in courts across the country and ultimately dropped.
The National Defense Authorization Act (NDAA), a $858 billion defense funding measure that President Biden signed at the conclusion of the previous year, repealed the requirement for military vaccinations.
On May 11, the Biden administration lifted the vaccination requirement for federal employees as the COVID public health emergency came to an end.
Due to the vaccine regulations, employees and members of the military around the nation lost their employment.
According to the Kaiser Family Foundation COVID-19 Vaccine Monitor in December last year, 38% of adults said that they either received the updated bivalent COVID booster dose or would soon.
Twelve percent of adults said they wanted to “wait and see” before getting the booster, while 13% said they only would if it was required. However, 9% said they wouldn’t get the new booster, and 27% were unvaccinated or partially vaccinated, thus not eligible for the booster.
SOURCES: ROIVANT SCIENCES, CTV NEWS, WHITE HOUSE, KAISER FAMILY FOUNDATION
You must be logged in to post a comment Login